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1 Drug description 
Generic/Brand name/ATC code:  
Ibrutinib/Imbruvica®/L01XE27 
 
Developer/Company:  
Distributed and marketed by Pharmacyclics Inc. and marketed by Janssen-
Cilag International NV. 
 
Description:  
Ibrutinib is a first-in-class, small-molecule inhibitor of Bruton’s Tyrosine 
Kinase (BTK). It covalently binds to and therefore irreversibly inhibits 
BTK. Since BTK is a signalling molecule of the B-cell antigen receptor and 
cytokine receptor pathways, the proliferation and survival, but also the mi-
gration and homing of malignant B-cells are inhibited [1].  
The recommended dosage of ibrutinib for the treatment of chronic lympho-
cytic leukaemia (CLL) is 420 mg taken orally once daily (three 140 mg cap-
sules once daily). Therapy should be continued until disease progression or 
unacceptable toxicities. Since bleedings, infections, renal failure and second 
primary malignancies have been reported, monitoring for occurrence of 
these adverse events is indicated throughout therapy [2].  
 
2 Indication 
Ibrutinib (Imbruvica®) for the treatment of patients with CLL who have 
received at least one prior therapy or in first-line in the presence of 17p de-
letion or TP53 mutation in patients unsuitable for chemo-immunotherapy. 
 
3 Current regulatory status 
In Europe, Imbruvica® was designated as an orphan medicinal product on 
the 26th of April 2012 for the treatment of mantle cell lymphoma, and on the 
12th March 2013 for the treatment of CLL. The Committee for Medicinal 
Products for Human Use (CHMP) formulated a positive recommendation 
on the 24th of July 2014 to grant market authorisation for ibrutinib for:  
 The treatment of adult patients with CLL who have received at 
least one prior therapy, or in first-line in the presence of 17p dele-
tion or TP53 mutation in patients unsuitable for chemo-
immunotherapy. 
 The treatment of adult patients with relapsed or refractory mantle 
cell lymphoma [3, 4].  
In the U.S., the FDA licensed ibrutinib with priority review for patients 
with:  
ibrutinib is a first-in-
class inhibitor of 
Bruton’s Tyrosine Kinase 
420 mg orally once daily 
ibrutinib for ≥second-
line CLL therapy or first-
line in patients with 17p 
deletion or TP53 
mutation 
positive CHMP 
recommendation for 
CLL in July 2014 
FDA licensing in July 
2014 for CLL 
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 CLL who have received at least one prior therapy in February 
2014 or with 17p deletion in July 2014.  
 mantle cell lymphoma who have received at least one prior thera-
py in November 2013 [2]. 
 
4 Burden of disease 
CLL belongs to the group of indolent B-cell non-Hodgkin lymphomas 
(NHL) and is the most common type of adult leukaemia in Western coun-
tries, accounting for approximately 25% to 30% of all leukaemias [5]. The 
median age at diagnosis is 72 years [6]. Thus, 70% of patients are older than 
65 years at diagnosis and CLL is rarely seen in younger persons, with fewer 
than 2% of patients being younger than 45 years at the time of diagnosis. 
The male to female ratio is 2:1 [5, 7]. 
Risk factors for developing CLL include older age, male sex, white ethnicity, 
family history of CLL or other blood and bone marrow cancers [8]. 
 
In the majority of cases, CLL is diagnosed incidentally by routine complete 
blood count examination, because most patients are asymptomatic at the 
time of diagnosis. Diagnosis is established by blood counts, blood smears 
and immunophenotyping of circulating B-lymphocytes [9]. The most com-
mon symptom is lymphadenopathy, followed by so-called “B” symptoms, in-
cluding fever, night sweats and weight loss. The life expectancy of patients 
with early-stage disease at diagnosis is greater than ten years, but decreases 
with advanced disease at diagnosis [10, 11]. 
 
There are two classification systems for the clinical staging of CLL, depend-
ing on standard laboratory tests and physical examination, including the Rai 
classification and the Binet staging system. The Rai classification distin-
guishes three stages: 
 
 low (formerly Rai stage 0): lymphocytosis 
 intermediate (formerly Rai stage I or II): lymphadenopathy, organ-
omegaly 
 high (formerly Rai stage IV and V) risk disease: anaemia, thrombo-
cytopenia.  
 
The Binet staging is subdivided into stages A, B and C [12]. The initiation of 
treatment is not recommended for asymptomatic early-stage disease (Rai 0, 
Binet A). In these patients, a watch-and-wait strategy with checks of blood 
cell counts and clinical examination every six months is recommended until 
there is evidence of disease progression; if the disease is stable, yearly inter-
vals are sufficient. In patients with intermediate and high-risk disease ac-
cording to the Rai classification, as well as patients with Binet stage B or C 
disease, the initiation of treatment is recommended, whereas some patients 
with intermediate disease or Binet stage B may also be monitored until the 
disease progresses [13]. Therapy is indicated when disease-specific symp-
toms (i.e., severe fatigue, night sweats, weight loss, painful lymphadenopa-
thy, or fever without infection), symptomatic/progressive anaemia and/or 
thrombocytopenia, progressive bulky disease (spleen > 6 cm below costal 
margin, lymph nodes > 10 cm) or increasing lymphocytosis with a lympho-
cyte doubling time of less than six months occur [14, 15].  
 
CLL most common form 
of leukaemia in 
industrialised countries 
affecting mostly 
patients ≥ 65 years 
risk factors: age, sex, 
ethnicity, family history, 
other cancers 
 
most patients are 
asymptomatic at 
diagnosis and are 
diagnosed incidentally 
two classification 
systems for CLL: Rai 
classification, Binet 
staging system 
watch and wait in early 
stage of disease 
 
therapy indicated when 
disease-specific 
symptoms, 
symptomatic/progressiv
e anaemia and/or 
thrombocytopenia, 
progressive bulky 
disease or increasing 
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In addition to these stages, prognosis depend on other factors such as serum 
markers thymidinekinase and beta-2 microglobulin, genetic markers includ-
ing immunoglobulin heavy chain variable (IGHV) mutational status and cy-
togenetic abnormalities detected by fluorescence in situ hybridisation (e.g., 
del[13q], del[11q], del[17p]), CD38 expression, and ZAP-70 expression [14, 
16]. 
Presence of unmutated IGHV, expression of CD38 (≥ 7% of B lymphocytes) 
and/or ZAP-70 are associated with a poor prognosis. Cytogenetic abnormali-
ties are present in about 80% of previously untreated CLL patients. 
Del(11q) (in about 18%) also leads to shorter median survival and to disease 
progression. Del(17p) can be found in about 7% of all patients and is associ-
ated with the poorest prognosis. Together with del(17p), patients with a mu-
tation of the p53gene (5–10% of the patients) have the poorest prognosis, re-
sulting in a median overall survival of about 2–3 years [17]. In contrast, ele-
vated levels of serum beta-2 microglobulin and del(13q) are predictors for a 
more favourable prognosis [14]. 
 
5 Current treatment 
The choice of first-line therapy depends on co-morbidities (measured, for 
example, by the Cumulative Illness Rating Scale), genetic status and renal 
function. 
If the disease has progressed on first-line therapy, further treatment will 
depend on the regimen administered previously, duration of remission, 
age and co-morbidities.  
Depending on the response to first-line therapy, relapsed and refractory 
disease can be distinguished. Relapsed disease is defined as a progressive 
disease after a period of six months or more after either a complete or par-
tial remission has been achieved [18]. If patients do not respond to thera-
py, i.e., they fail to achieve either a partial or complete remission with 
therapy, or if they develop a disease progression within six months of ther-
apy, they have refractory disease. 
 
Treatment options for refractory/relapsed CLL include: 
 Second- and subsequent-line chemotherapy: 
o Combination therapy with fludarabine, cyclophospha-
mide and rituximab (FCR) if patients can tolerate it or if 
they responded well (PFS > 24 months) to first-line FCR 
[19] or bendamustine and rituximab (well-established, 
but few RCTs).  
o For older patients or those with co-morbidities who are 
not considered well enough for intensive cytotoxic chem-
otherapy (e.g., FCR), there is no recognised standard 
treatment. Options include chlorambucil with rituximab 
(in patients previously untreated with chemotherapy), 
bendamustine (with or without rituximab) or dose-
reduced FCR. 
o Idelalisib in combination with rituximab (positive 
CHMP decision was issued in July 2014).  
 Biological therapy: 
o Rituximab may be used in combination with chemother-
apy agents. 
80% of patients show 
cytogenetic 
abnormalities 
poor prognostic factors: 
unmutated IGHV, 
Del(17p), del(11q) 
 
treatment options 
depending on stage, 
age, cytogenetic lesions, 
other diseases  
treatment options for 
CLL 
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o Other anti-CD20 monoclonal antibodies, such as ofatu-
mumab, may be considered; ofatumumab is currently be-
ing used predominantly in patients who are refractory to 
rituximab and alemtuzumab. 
o Allogeneic stem-cell transplantation should be consid-
ered for fit patients with high-risk CLL and should ideal-
ly be performed in the setting of a remission. 
o Alemtuzumab and methylprednisolone for patients with 
high-risk disease (with early relapse or TP53 dele-
tion/mutation) when tolerated, or alemtuzumab with or 
without corticosteroids as an option for fitter patients 
who have failed other conventional therapies. However, 
the drug was voluntarily withdrawn by the marketing au-
thorisation holder in Europe in 2012 [20].  
 Radiotherapy: rarely used, but may be indicated for patients with 
enlarged lymph nodes, an enlarged spleen or prior to bone mar-
row transplant [1]. 
 
 
6 Evidence 
A systematic literature search was conducted in four databases (Ovid Med-
line, Embase, Cochrane Library, CRD Database) on the 22nd of July 2014. 
Search terms were Ibrutinib, pci-32765, pci 32765, pci32765, imbruvica 
and 'chronic lymphocytic leukemia', 'chronic lymphocytic leukemias', 
'chronic lymphocytic leukaemia' or 'chronic lymphocytic leukaemia. The 
systematic search yielded 235 references overall, and the manufacturer 
submitted seven publications overall. Of these, all but two had already 
been identified by the systematic literature search, resulting in 237 refer-
ences overall. Of all identified articles, two references were included: one 
phase III trial [21] and one phase II study [22].  
 
 
6.1 Efficacy and safety – Phase III studies 
Table 1: Summary of efficacy 
Study title  
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [21, 23] 
Study  
identifier 
Clinical Trials No: NCT01578707; PCYC-1112-CA, EudraCT No: 2012-000694-23; 
RESONATE 
Design Multicentre (67 sites in the U.S., Europe and Australia), open-label, phase 3 study 
stratified according to whether they had resistance to purine analogue 
chemoimmunotherapy (defined as no response or a relapse within 12 months after the 
last dose of a purine analogue) and whether they had a chromosome 17p13.1 deletion 
Duration  Enrolment: June 2012–April 2013 
Median follow-up: 9.4 months (range 0.1 – 16.6) 
Cut-off dates for analyses: NA 
Hypothesis Superiority 
Number of required events was based on a target hazard ratio for progression or death 
of 0.60, as calculated with the use of a two-sided log-rank test at an alpha level of 
0.05, with a study power of at least 90%. Assuming median PFS for the ofatumumab 
arm is eight months as measured from the date the patient is randomised, a target 
systematic search in 
four databases yielded 
235 references  
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hazard ratio of 0.6 corresponds to a 66.7% increase in median PFS for the ibrutinib arm 
relative to the ofatumumab arm (increase from 8 months to 13.31 months). 
Funding Pharmacyclics and Janssen 
Treatment 
groups 
Overall study participants = 391 
Intervention 
(n = 195) 
oral ibrutinib (at a dose of 420 mg once daily) until disease 
progression or the occurrence of unacceptable toxic effects  
Control 
(n = 196) 
iv ofatumumab for up to 24 weeks at an initial dose of 300 mg 
at week 1, followed by a dose of 2000 mg weekly for seven 
weeks and then every four weeks for 16 weeks 
Endpoints 
and 
definitions 
Progression-free 
survival 
(primary outcome) 
PFS assessed by independent review committee per 
International Workshop on Chronic Lymphocytic 
Leukaemia 2008 criteria [18] 
Overall survival OS time from date of randomisation until date of death due 
to any cause 
Response rate ORR defined as the proportion of patients who achieve 
complete response (CR), complete response with 
incomplete bone marrow recovery (CRi), nodular partial 
response (nPR), or partial response (PR) per IWCLL 
2008 criteria over the course of the study as evaluated 
by an IRC 
Patient-reported 
outcome 
PRO EORTC QLQ-30: change in scores from baseline to each 
assessment for all scales  
FACiT: Fatigue change in scores from baseline to each 
assessment  
EQ-5D: change in weighted utility score from baseline to 
each assessment 
Results and analysis 
Analysis  
description 
The primary analysis was a two-sided log-rank test stratified according to the presence 
or absence of the chromosome 17p13.1 deletion and the disease refractory status at 
randomisation. 
Analysis  
population 
Inclusion  patients with CLL or SLL requiring therapy if they had received 
at least one previous therapy and were considered to be 
inappropriate candidates for purine analogue treatment 
because they had a short progression free interval after 
chemoimmunotherapy or because they had coexisting 
illnesses, an age of 70 years or more, or a chromosome 17p13 
deletion 
 ECOG ≤ 2 
 absolute neutrophil count of at least 750 cells per microlitre, a 
platelet count of at least 30,000 cells per microlitre, and 
adequate liver and kidney function 
Exclusion  therapy with warfarin or strong CYP3A4/5 inhibitors 
Characteristics  Ibrutinib vs. Ofatumumab 
Patients with SLL; % 
Median age (range); yrs:  
CIRS score > 6; %:  
ECOG 0/1; %:  
Bulky disease ≥ 5 cm; % 
Chromosome 11(q22.3) del; %:  
Chromosome 17(p13.1) del; %:  
Previous therapies: 
5 vs. 4 
67 (30 – 86) vs. 67 (37 – 88) 
32 vs. 32 
41/59 vs. 41/59 
64 vs. 52 
32 vs. 30 
32 vs. 33 
Median number of previous 
therapies (range): 
3 (1 – 12) vs. 2 (1 – 13) 
 
≥ 3 previous therapies; %: 53 vs. 46 
Type of previous therapy; %  
Alkylator 93 vs. 88 
Bendamustine 43 vs. 37 
Purine analogue 85 vs. 77 
Anti-CD20 94 vs. 90 
Alemtuzumab 21 vs. 17 
Allogeneic transplantation 2 vs. 1 
Horizon Scanning in Oncology 
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Median time from last therapy 
(range); months 
8 (1 – 140) vs. 12 (0 – 184) 
 
Resistance to purine analogues1; 
% 
45 vs. 45 
Descriptive 
statistics 
and 
estimated 
variability 
Treatment group Ibrutinib Ofatumumab 
Number of subjects N = 195 N = 196 
Median PFS; months NR 8.1 
PFS at six months; % 88 65 
OS at 12 months; % 90 81 
ORR; number (%) 
PR 
PR + lymphocytosis 
SD 
PD  
 
83 (43) 
39 (20) 
63 (32) 
5 (3) 
 
8 (4) 
- 
153 (78) 
20 (10) 
Effect 
estimate per 
comparison 
Comparison groups  Ibrutinib vs. Ofatumumab 
PFS HR 0.22 
95% CI 0.15 – 0.32 
P value < 0.001 
OS HR 0.43 
95% CI 0.24 – 0.79 
P value 0.005 
PR OR 17.4 
95% CI  8.1 – 37.3 
P value < 0.001 
PRO Point estimate NA 
Variability NA 
P value NA 
Subgroup analyses   
PFS – del(17)  N = 127 
HR 0.25 
95% CI 0.14 – 0.45 
P value NA 
PFS - refractory to purine 
analogues 
 N = 175 
HR 0.18  
95% CI 0.10 – 0.32 
P value NA 
Abbreviations: CI = confidence interval; CIRS = Cumulative Illness Rating Scale (ranging from 0 to 52, with higher scores indi-
cating worse health status); CLL = chronic lymphocytic leukaemia; ECOG = Eastern Cooperative Oncology Group; FACIT = 
Functional Assessment of Chronic Illness Therapy; HR = hazard ratio; iv = intravenous; N = number; NA = not available; NR 
= not reached; OR = odds ratio; ORR = overall response rate; OS = overall survival, PFS = progression free survival; PR = 
partial response; PRO = patient-reported outcome; SLL = small lymphocytic lymphoma 
1
 = defined as no response or a relapse within 12 months after the last dose of a CD20-based chemo-immunotherapy regimen that 
included a purine analogue.  
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Table 2: Most frequent adverse events (any grade ≥ 20%; grade 3 or 4≥ 5%) 
RESONATE [21, 24] 
Grade  (according  
to NCI CTC version 
4.0) 
Outcome, n (%) Ibrutinib 
(n = 195) 
Ofatumumab 
(n = 191) 
Any Grade Any adverse event 194 (99) 187 (98 
Diarrhoea 93 (48) 34 (18) 
Fatigue 54 (28) 57 (30) 
Nausea 51 (26) 35 (18) 
Pyrexia  46 (24) 28 (15) 
Anaemia 44 (23) 33 (17) 
Neutropenia 42 (22) 28 (15) 
Cough  38 (19) 44 (23) 
Infusion-related reaction 0 53 (28) 
Infections NA (70) NA (54) 
Bleeding-related NA (44) NA (12) 
Grade 3 or 4 
 
Any adverse event 99 (51) 74 (39) 
≥ 1 adverse event  NA (57) NA (47) 
Anaemia 9 (5) 15 (8) 
Neutropenia 32 (16) 26 (14) 
Thrombocytopenia 11 (6) 8 (4) 
Pneumonia 13 (7) 9 (5) 
Other ≥ 1 SAE 81 (42) 58 (30)  
Treatment discontinuation 
due to AEs 
NA (4) NA (4) 
Fatal AEs NA (4) NA (5) 
Abbreviations: NA = not available; SAE = serious adverse event; AE = adverse event  
 
 
The RESONATE trial, a phase III study, compared ibrutinib to ofatu-
mumab in 391 previously treated patients with relapsed or refractory CLL 
or small lymphocytic lymphoma (SLL) [21]. The median number of previ-
ous therapies was three in the ibrutinib group and two in the ofatumumab 
group, including alkylators, purine analogues, anti-CD20 therapies and 
bendamustine. The median time from the last therapy was eight months in 
the intervention group and 12 in the control group, but in both groups 45% 
of the individuals were resistant to purine analogues. All patients included 
had an ECOG PS of 0 or 1, and 32% in each group had a CIRS score > 6. 
About 60% of patients had chromosomal abnormalities, but stratification 
was based on the presence of chromosomal del(17p) and resistance to purine 
analogue chemoimmunotherapy.  
The median PFS, the primary outcome, was not yet reached in the ibrutinib 
group at a follow-up of 9.4 months, but was 8.1 months in the ofatumumab 
group. The hazard ratio was 0.22 (95% CI 0.15-0.32; p < 0.001). These bene-
fits were also consistent in several subgroup analyses, including, for exam-
ple, disease refractory to purine analogues, number of previous therapies, 
presence of bulky disease, chromosome deletions and Rai stage. Overall sur-
vival also yielded statistically significant improvements for ibrutinib (HR 
0.43, 95% CI 0.24-0.79; p < 0.005). At 12 months, the overall survival rate 
was 90% in the intervention group and 81% in the control group. However, 
OS results may be influenced by the fact that approximately four months af-
ter the last patient was randomised, crossing-over to the ibrutinib group was 
allowed and 57 patients from the former ofatumumab group overall received 
the BTK inhibitor [24]. In terms of response rates, 43% in the ibrutinib 
RESONATE trial, phase 
III, compared ibrutinib 
to ofatumumab in 391 
previously treated 
patients with relapsed 
or refractory CLL 
hazard ratio of PFS was 
0.22, favouring ibrutinib 
group 
 
risk of death reduced by 
57% in ibrutinib group 
 
cross-over from 
ofatumumab group to 
ibrutinib was allowed 
 
partial response in 43% 
in ibrutinib and 4% and 
in ofatumumab group 
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group and 4% in the ofatumumab group achieved a partial response, where-
as 32% and 78% respectively had a stable disease.  
Adverse events (AE) of any grade occurred in nearly all patients of both 
groups, and at least one serious AE was observed in 57% in the ibrutinib 
group, compared to 47% in the ofatumumab group. The most frequent AEs 
of any grade were diarrhoea, fatigue, nausea and pyrexia in the ibrutinib 
group, and infusion-related reactions, cough and fatigue in the ofatumumab 
group. Discontinuation due to AEs, as well as fatal events, were similar in 
both groups, but treatment exposure was 3.3 months longer in the ibrutinib 
group than in the ofatumumab group. Cutaneous second primary malignan-
cies (basal-cell and squamous-cell carcinomas) were observed in 4% and 2%, 
and non-skin cancers in 3% and 1%. Richter’s transformation, which is the 
development of an aggressive large-cell lymphoma out of an underlying 
CLL, occurred in two patients in each of the two groups.  
Based on the results of this interim analysis, the independent data and safety 
monitoring committee recommended that the trial be stopped and that any 
patients on ofatumumab be offered treatment with ibrutinib. 
 
6.2 Efficacy and safety – further studies 
A phase Ib-II open-label study investigated ibrutinib in 85 patients overall 
with CLL or SLL [22]. Participants were allocated to three cohorts. The first 
two cohorts (27 and 24 patients) received a fixed daily dose of 420 mg of ib-
rutinib. Participants had received at least two previous therapies, including 
a purine analogue. In the third group, 32 patients received 840 mg daily un-
til the onset of disease progression or unacceptable toxicity. This cohort was 
considered as high-risk patients, because they did not respond to a chemo-
immunotherapy or had progressed within 24 months after completion of the 
regimen. 65% had advanced disease, about 70% had deletions in either 
chromosome 17 or 11, and the median number of previous therapies was 4. 
Safety in the first two cohorts was the primary endpoint. The most common 
AEs were diarrhoea (49%), upper respiratory tract infection (33%), fatigue 
(32%) and cough (31%). The most common AEs ≥ grade 3 were pneumonia 
(12%), dehydration (6%) and neutropenia (15%). The overall response rate 
was 71%, regardless of dosage. The response was not influenced by high-risk 
features with the exception of unmutated immunoglobulin variable-region 
heavy-chain gene (IGHV). Moreover, the estimate of PFS at 26 months was 
75% and the OS rate 83% at a median follow-up of 20.9 months. 
 
7 Estimated costs 
Costs for Imbruvica® in Austria are not known yet.  
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8 Ongoing research 
On http://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ctr-
search/ four ongoing phase III trials were identified for relapsed or refracto-
ry CLL patients: 
 NCT01611090: to examine the safety and efficacy of ibrutinib ad-
ministered in combination with bendamustine and rituximab in 
patients with relapsed or refractory CLL or SLL. Estimated prima-
ry completion date: August 2015. 
 NCT01973387: to evaluate the efficacy and safety of ibrutinib ver-
sus rituximab in adult Asia-Pacific region patients with relapsed or 
refractory CLL or SLL. Estimated primary completion date: Au-
gust 2015. 
 NCT01724346: open-label extension study in patients 65 years or 
older with CLL or SLL who participated in study PCYC-1115-CA 
(PCI-32765 versus chlorambucil). Estimated primary completion 
date: June 2015. 
 NCT01804686: to collect long-term safety and efficacy data for par-
ticipants treated with PCI-32765 (ibrutinib) and to provide ongoing 
access to PCI-32765 for participants who are currently enrolled in 
PCI-32765 studies that have been completed according to the par-
ent protocol, are actively receiving treatment with PCI-32765, and 
who continue to benefit from PCI-32765 treatment. Estimated pri-
mary completion date: January 2016. 
 
Several phase III trials are ongoing on previously untreated CLL patients 
(NCT01722487), also in combination with other agents such as bevacizumab 
or rituximab (NCT01886872, NCT02048813). Several phase II studies are 
listed, including hairy cell leukaemia, multiple myeloma, marginal cell 
lymphoma, follicular lymphoma and small lymphocytic lymphoma.  
 
9 Commentary 
Ibrutinib, a first-in-class inhibitor of BTK, was licensed under priority re-
view by the FDA for patients with CLL who have received at least one prior 
therapy in February 2014 and for patients with 17p deletion in July 2014. It 
was the second drug that received breakthrough designation. 
In Europe, the CHMP recently (in July 2014) formulated a positive opinion 
recommending to grant market authorisation for the treatment of adult pa-
tients with CLL who have received at least one prior therapy, or as first-line 
therapy in the presence of 17p deletion or TP53 mutation in patients unsuit-
able for chemoimmunotherapy.  
4 ongoing phase III trials 
identified for relapsed or 
refractory CLL patients 
under investigation for 
untreated patients and 
for other malignancies 
licensed in the US and 
positive CHMP decision 
in Europe in July 2014  
for CLL patients with ≥ 
one prior therapy, or as 
first-line therapy in the 
presence of 17p deletion 
or TP53 
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These decisions were primarily based on the results of the RESONATE trial, 
a phase III study. 391 previously treated patients were randomised to either 
ibrutinib orally or ofatumumab intravenously. Patients were considered un-
suitable for treatment or retreatment with purine analogue-based therapy 
and about one-third had del(17p). At a follow-up of 9.4 months, the risk of 
progression or death from any cause was reduced by 78% in the ibrutinib 
group, a finding that was consistent in subgroup analyses including disease 
refractory to purine analogues, number of previous therapies, presence of 
bulky disease and chromosome deletions including del(17p). With a statisti-
cally significant reduction of 57% in the risk of death, OS also favoured the 
intervention group. In terms of response, no complete response was ob-
served, but partial responses were experienced by 43% in the ibrutinib 
group, compared to 4% in the ofatumumab group. 
The most frequent AEs of any grade associated with ibrutinib were diar-
rhoea, fatigue, fever and nausea. More patients in the ibrutinib group than 
in the ofatumumab group had at least one AE of grade ≥ 3 (57% versus 
47%). Grade ≥ 3 AEs more commonly observed in the ibrutinib group were 
diarrhoea (4% vs. 2%) and irregular or rapid heart rate (3% vs. 0%). Bleed-
ing-related AEs of any grade were also more common in the ibrutinib group 
than in the ofatumumab group (44% vs. 12%). 
Besides results for ibrutinib monotherapy for previously treated patients 
with relapsed CLL, the BTK inhibitor is already under evaluation for fur-
ther indications. Phase III studies are underway, investigating its efficacy in 
previously untreated, sometimes including elderly CLL patients as well. 
Another subject of investigation is if combination therapies will increase 
depth of remission [25]. For example, adding cytotoxic drugs to ibrutinib 
may accelerate time to remission [26] and the combination with CD20 anti-
bodies may shorten the time to response, because ibrutinib redistributes 
CLL cells from lymph nodes and tissue into the peripheral blood. Thus, 
these cells may become more sensitive to CD20 antibodies (e.g., ofatu-
mumab) [27, 28].  
Besides the potential for improved clinical outcomes, the rationale for com-
bination therapies rather than monotherapy with ibrutinib is to avoid the 
development of resistance. The mechanism is not yet understood; de-novo 
mutations, as well as selection from subfractions of predominantly pre-
existing, malignant clones, are discussed [29]. The frequency of drug re-
sistance to monotherapy is currently considered as low, but due to the short-
follow-up, a considerable number of patients may develop resistance over 
time [27]. Combining therapies with different modes of action may therefore 
be a means for preventing resistance [30].  
Another question concerns the risk of disease transformation [28]. Even 
though patients progressing whilst on ibrutinib therapy still respond to oth-
er available treatment options, Richter’s transformation after ibrutinib is as-
sociated with a poor prognosis and only short responses have been observed 
on further lines of therapy [31]. In the phase III trial, however, two patients 
in each group experienced a transformation to an aggressive large-cell lym-
phoma. 
Since patients seem to respond to continued treatment and rapid tumour 
progression has been occasionally observed in relapsing patients after ibru-
tinib therapy was stopped, ibrutinib may be administered for a long period 
of time [25, 27], the need to further establish its side effect profile is high-
lighted. Unlike other available agents for CLL, the myelosuppressive poten-
tial of ibrutinib is low; therefore, diarrhoea, fatigue and nausea were side ef-
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fects most often observed in the RESONATE trial [28]. These AEs were 
mainly mild to moderate and are considered manageable in the outpatient 
setting. However, in contrast to temporarily limited side effects associated 
with chemotherapy, these side effects can compromise quality of life in the 
long-term when ibrutinib is continuously used [29]. However, data regard-
ing these outcomes are not available.  
In addition, due to the rather short observation time of ibrutinib therapy, 
long-term side effects are not known yet [28]. Secondary cancers, for exam-
ple, occurred in the ibrutinib group in up to 4% of patients, compared to 2% 
in the ofatumumab group in the RESONATE trial. Lastly, it has to be de-
termined whether a manageable side effect profile in the short- and long-
term can be maintained when ibrutinib is administered in combination 
with, e.g., chemotherapy [29]. 
Another concern is the costs for ibrutinib. No price estimates are available 
for Europe yet, but in the U.S., one pill costs $ 91, which adds up to $ 8,200 
(≈ € 6,185) for one month of ibrutinib therapy for CLL [32]. Even though 
prices will likely be lower in Europe, affordability in the long-term and/or in 
combination with other targeted agents remains an issue [29, 30]. Therefore, 
monotherapy or combination therapies using ibrutinib only for a limited 
treatment duration may be less expensive alternatives [27, 28]. Of interest 
will also be the comparison of costs associated with different therapeutic 
strategies, considering not only established regimens but also new agents—
for example, idelalisib (Zydelig®) was just approved by the FDA for recur-
rent/relapsed patients in July 2014, and further BTK inhibitors are in devel-
opment [14, 27, 33]. 
New treatment options for CLL, primarily for difficult-to-treat patients with 
relapsed or refractory disease or with poor prognostic characteristics such as 
del(17p) or p53 mutations are needed. Foremost for these patients, ibrutinib 
offers an alternative.  
 
long-term side-effects of 
mono- and combination 
therapy unknown 
costs unknown but may 
be high especially when 
administered for long 
periods and/or in 
combination with other 
agents 
new treatment options 
for difficult-to-treat CLL 
patients needed 
ibrutinib will soon offer 
a new alternative 
Horizon Scanning in Oncology 
14 LBI-HTA | 2014 
References 
 
 
[1]   NIHR HSC. Ibrutinib for relapsed or refractory chronic lymphocytic leukaemia – second line. 
Birmingham: NIHR Horizon Scanning Centre (NIHR HSC) 2013.  
[2]   U.S. Food and Drugs Administration. Imbruvica - Highlights of prescribing information 2014  [cited 
23. July 2014]; Available from: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205552Orig2lbl.pdf  
[3]   European Medicines Agency. Applications for new human medicines under evaluation by the 
Committee for Medicinal Products for Human Use July 2014.  2014  [cited 23. July 2014]; Available 
from: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2014/07/WC500169655.pdf  
[4]   European Medicines Agency. Imbruvica.  2014  [cited 25 August 2014]; Available from: 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003791/smops/
Positive/human_smop_000721.jsp&mid=WC0b01ac058001d127  
[5]   Rai K, Keating M. Up to Date - Epidemiology and clinical manifestations of chronic lymphocytic 
leukemia.  2014  [cited 17.04.2014]; Available from: 
http://www.uptodate.com/contents/epidemiology-and-clinical-manifestations-of-chronic-
lymphocytic-leukemia  
[6]   Molica S, Brugiatelli M, Morabito F, Ferrara F, Iannitto E, Di Renzo N, et al. Treatment of elderly 
patients with chronic lymphocytic leukemia: An unmet cinical need. Expert Review of Hematology. 
2013;6(4):441-9.  
[7]   Cancer Network. Chronic lymphocytic leukemia and hairy cell leukemia.  2014  [cited 17.04.2014]; 
Available from: 
http://www.cancernetwork.com/login?referrer=http%3A//www.cancernetwork.com%2Fchronic-
lymphocytic-leukemia-and-hairy-cell-leukemia  
[8]   Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. 
Curr Opin Immunol. 2008 Aug;20(4):444-9.  
[9]   Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and 
treatment. Am J Hematol. 2013 Sep;88(9):803-16.  
[10]   Maddocks KJ, Lin TS. Update in the management of chronic lymphocytic leukemia. J Hematol 
Oncol. 2009;2:29.  
[11]   Migkou M, Dimopoulos MA, Gavriatopoulou M, Terpos E. Applications of monoclonal antibodies 
for the treatment of hematological malignancies. Expert Opin Biol Ther. 2009 Feb;9(2):207-20.  
[12]   Rai K, Keating M. Up to Date - Staging and prognosis of chronic lymphocytic leukemia.  2014  [cited 
17.04.2014]; Available from: http://www.uptodate.com/contents/staging-and-prognosis-of-chronic-
lymphocytic-leukemia?source=search_result&search=CLL&selectedTitle=1~150  
[13]   Rai K, Keating M. Up to Date - Overview of the treatment of chronic lymphocytic leukemia.  2014  
[cited 17.04.2014]; Available from: http://www.uptodate.com/contents/overview-of-the-treatment-of-
chronic-lymphocytic-
leukemia?source=search_result&search=overview+of+the+treatment+of+chronic+lymphocytic+
leukemia&selectedTitle=1~150  
[14]   National Comprehensive Cancer Network. NCCN Guidelines Version 2.2014 Non-Hodgkin’s 
Lymphomas; 2014.  
[15]   Wendtner CM, Dreger P, Gregor M, Greil R, Knauf WU. Chronische Lymphatische Leukämie 
(CLL) Leitlinie. Berlin: DGHO Deutsche Gesellschaft für Hämatologie und Medzinische Onkologie 
e.V. 2012.  
[16]   MedImpact. Gazyva (obinutuzumab).  2013  [cited 17.04.2014]; Available from: 
http://www.ishnonline.com/downloads/Gazyva_Drug_Review.pdf  
LBI-HTA | 2014 15 
[17]   Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, Group EGW. Chronic lymphocytic 
leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of 
oncology : official journal of the European Society for Medical Oncology / ESMO. 2011 Sep;22 Suppl 
6:vi50-4.  
[18]   Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for 
the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International 
Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working 
Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56.  
[19]   Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. 
Hematology / the Education Program of the American Society of Hematology American Society of 
Hematology Education Program. 2010;2010:481-8.  
[20]   European Medicines Agency. Public statement - MabCampath (alemtuzumab) Withdrawal of the 
marketing authorisation in the European Union 2012.  
[21]   Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus 
ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 Jul 
17;371(3):213-23.  
[22]   Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with 
ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42.  
[23]   Byrd JC BJ, O’Brien S, et al. Protocol for: Ibrutinib versus ofatumumab in previously treated chronic 
lymphoid leukemia. . N Engl J Med. 2014(271):213-23.  
[24]   Byrd JC BJ, O’Brien S, et al. Supplement to: Ibrutinib versus ofatumumab in previously treated 
chronic lymphoid leukemia. N Engl J Med. 2015(371):213-23.  
[25]   McDermott J, Jimeno A. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle 
cell lymphoma. Drugs Today (Barc). 2014 Apr;50(4):291-300.  
[26]   Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 
2014 Mar;9(1):44-9.  
[27]   Hutchinson CV, Dyer MJS. Breaking good: the inexorable rise of BTK inhibitors in the treatment of 
chronic lymphocytic leukaemia. Br J Haematol. 2014 Jul;166(1):12-22.  
[28]   Burger JA, Buggy JJ. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leuk Lymphoma. 2013 
Nov;54(11):2385-91.  
[29]   Spaargaren M, de Rooij MF, Kater AP, Eldering E. BTK inhibitors in chronic lymphocytic leukemia: 
a glimpse to the future. Oncogene. 2014 Jun 23.  
[30]   Farooqui MZ, Wiestner A. Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert 
Opinion on Orphan Drugs. 2013;1(11):925-33.  
[31]   Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the Era of Targeted Therapy for 
Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician. J Clin Oncol. 2014 Jul 21.  
[32]   Comer B. Ibrutinib's Breakthrough to Market.  2013  [cited 26 August 2014]; Available from: 
http://blog.pharmexec.com/2013/11/25/ibrutinibs-breakthrough-to-market/  
[33]   U.S. Food and Drugs Administration. Highlights of prescribing information - Zydelig; 2014.  
 
 
